Related Experiment Video
Updated: Jun 14, 2026

Analysis of Retinoic Acid-induced Neural Differentiation of Mouse Embryonic Stem Cells in Two and Three-dimensional Embryoid Bodies
Published on: April 22, 2017
Antagonists of retinoic acid and BMP4 affect fetal mouse osteogenesis and odontoblast differentiation
Despina S Koussoulakou1, Lukas H Margaritis, Stauros L Koussoulakos
1Department of Cell Biology and Biophysics, Faculty of Biology, N. & K. University of Athens, Panepistimiopolis 15784, Greece.
Abstract:
Retinoic acid and bone morphogenetic protein (BMP4) are endogenous factors indispensable for the physiological development of vertebrates. The proximate aim of the present study was to investigate whether the natural compound citral (a retinoic acid synthesis inhibitor) and a monoclonal, anti-BMP4 antibody, administered to pregnant mice affect in the fetuses cranial osteogenesis and odontoblast differentiation. The present investigation was motivated by the fact that, retinoic acid inhibitors and BMP4 neutralizers may frequently contact human tissues (both intentional and unintentional, and/or unconsciously) inducing unanticipated effects. Our ultimate goal is the prevention of side effects and, future clinical implementation of the results. To this end, pregnant, white mice (balb-c Mus musculus) were intra-abdominally injected with either citral or anti-BMP4 antibody at the 9th gestational day. Newborns were processed within 5h, postnatal. Results were evaluated (a) macroscopically, (b) stereoscopically, following histochemical double staining of cartilage and osseous tissues and, (c) microscopically after (c(1)) histological staining of paraffin sections, and, (c(2)) immunohistochemical detection of apoptosis. Data indicate that in vivo administration of citral (biomimicking hypovitaminosis A) caused restriction/retardation of cranial chondrogenesis and osteogenesis. Apoptosis was not detected in teeth tissues. In vivo administration of anti-BMP4 antibody resulted in a transitory interference with the normal course of odontoblast differentiation and the production of pre-dentin, whereas, delay in the ossification also included the alveoli. Animals inspected in adulthood displayed a fairly normal phenotype. It is concluded that those two substances, under their concentrations experienced, are quite safe for the public.
Insights
Citral and anti-BMP4 antibody treatments in pregnant mice showed minor, temporary effects on fetal cranial bone development and tooth formation, concluding both substances are safe at tested doses.
Area of Science:
- Developmental biology
- Osteogenesis research
- Toxicology studies
Background:
- Retinoic acid and bone morphogenetic protein (BMP4) are vital for vertebrate development.
- Potential human exposure to retinoic acid inhibitors and BMP4 neutralizers necessitates safety assessments.
Purpose of the Study:
- To evaluate the impact of citral (retinoic acid synthesis inhibitor) and anti-BMP4 antibody on fetal cranial osteogenesis and odontoblast differentiation.
- To determine the safety of these compounds for potential clinical use by assessing side effects.
Main Methods:
- Pregnant mice were injected with citral or anti-BMP4 antibody on day 9 of gestation.
- Newborns were analyzed macroscopically, stereoscopically (histochemistry), and microscopically (histology, immunohistochemistry for apoptosis).
Main Results:
- Citral administration mimicked hypovitaminosis A, causing cranial chondrogenesis and osteogenesis retardation; no apoptosis was observed in teeth.
- Anti-BMP4 antibody caused transient interference with odontoblast differentiation and pre-dentin production, with delayed ossification in alveoli.
- Adult offspring exhibited largely normal phenotypes, indicating resilience to the treatments.
Conclusions:
- Citral and anti-BMP4 antibody, at the tested concentrations, demonstrate a low risk profile for fetal development.
- These findings support the safety of citral and anti-BMP4 antibody, paving the way for future clinical considerations.

